[go: up one dir, main page]

WO2025052177A3 - Nouvelle composition et méthodes de traitement d'une maladie neurodégénérative - Google Patents

Nouvelle composition et méthodes de traitement d'une maladie neurodégénérative Download PDF

Info

Publication number
WO2025052177A3
WO2025052177A3 PCT/IB2024/000496 IB2024000496W WO2025052177A3 WO 2025052177 A3 WO2025052177 A3 WO 2025052177A3 IB 2024000496 W IB2024000496 W IB 2024000496W WO 2025052177 A3 WO2025052177 A3 WO 2025052177A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating
neurodegenerative disease
novel composition
pten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/000496
Other languages
English (en)
Other versions
WO2025052177A2 (fr
Inventor
Man Lok Andrew CHAN
Zhining Li
Lisha LI
Shira KNAFO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinese University of Hong Kong CUHK
Original Assignee
Chinese University of Hong Kong CUHK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinese University of Hong Kong CUHK filed Critical Chinese University of Hong Kong CUHK
Publication of WO2025052177A2 publication Critical patent/WO2025052177A2/fr
Publication of WO2025052177A3 publication Critical patent/WO2025052177A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des méthodes pour inhiber l'interaction entre deux molécules de protéine, PTEN et PSD-95, dans des neurones. L'inhibition de l'interaction entre PTEN et PSD-95 est utilisée dans des méthodes de traitement de la maladie d'Alzheimer. Les compositions comprennent de l'acide isochlorogénique B, de l'acide isochlorogénique C et de l'amarante.
PCT/IB2024/000496 2023-09-06 2024-09-06 Nouvelle composition et méthodes de traitement d'une maladie neurodégénérative Pending WO2025052177A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363580829P 2023-09-06 2023-09-06
US63/580,829 2023-09-06

Publications (2)

Publication Number Publication Date
WO2025052177A2 WO2025052177A2 (fr) 2025-03-13
WO2025052177A3 true WO2025052177A3 (fr) 2025-04-17

Family

ID=94923116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/000496 Pending WO2025052177A2 (fr) 2023-09-06 2024-09-06 Nouvelle composition et méthodes de traitement d'une maladie neurodégénérative

Country Status (1)

Country Link
WO (1) WO2025052177A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050042A1 (fr) * 1999-02-22 2000-08-31 Apologic, Incorporated Procedes de traitement de maladies liees a l'apolipoproteine e
US20030186946A1 (en) * 2002-01-29 2003-10-02 Cooper Garth James Smith Suppression of cytotoxic protein conformers
US20180028482A1 (en) * 2016-07-12 2018-02-01 Kodimule Shyam Prasad Chlorogenic acid composition and method for its use in the treatment of alzheimer's disease
CN109674777A (zh) * 2019-01-16 2019-04-26 中国科学院成都生物研究所 异绿原酸类化合物在制备神经退行性疾病和忧郁症的药物中的应用
WO2023068176A1 (fr) * 2021-10-20 2023-04-27 国立大学法人九州大学 Agent favorisant la prolifération neuronale et son utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050042A1 (fr) * 1999-02-22 2000-08-31 Apologic, Incorporated Procedes de traitement de maladies liees a l'apolipoproteine e
US20030186946A1 (en) * 2002-01-29 2003-10-02 Cooper Garth James Smith Suppression of cytotoxic protein conformers
US20180028482A1 (en) * 2016-07-12 2018-02-01 Kodimule Shyam Prasad Chlorogenic acid composition and method for its use in the treatment of alzheimer's disease
CN109674777A (zh) * 2019-01-16 2019-04-26 中国科学院成都生物研究所 异绿原酸类化合物在制备神经退行性疾病和忧郁症的药物中的应用
WO2023068176A1 (fr) * 2021-10-20 2023-04-27 国立大学法人九州大学 Agent favorisant la prolifération neuronale et son utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DI GAO ET AL.: "Analysis of chemical constituents in an herbal formula Jitong Ning Tablet", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 140, 19 March 2017 (2017-03-19), XP029984490, DOI: 10.1016/j.jpba.2017.03.033 *
FUJIWARA HIRONORI, TABUCHI MASAHIRO, YAMAGUCHI TAKUJI, IWASAKI KOH, FURUKAWA KATSUTOSHI, SEKIGUCHI KYOJI, IKARASHI YASUSHI, KUDO Y: "A traditional medicinal herb Paeonia suffruticosa and its active constituent 1,2,3,4,6-penta- O -galloyl-β-d-glucopyranose have potent anti-aggregation effects on Alzheimer’s amyloid β proteins in vitro and in vivo", JOURNAL OF NEUROCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 109, no. 6, 1 June 2009 (2009-06-01), GB , pages 1648 - 1657, XP093059156, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2009.06069.x *
NATH SOUMAV, ROY PRITI, MANDAL RAKI, ROY RAJAT, BUELL ALEXANDER K., SENGUPTA NEELANJANA, TARAFDAR PRADIP K.: "Hydroxy‐Porphyrin as an Effective, Endogenous Molecular Clamp during Early Stages of Amyloid Fibrillization", CHEMISTRY - AN ASIAN JOURNAL, WILEY-VCH, HOBOKEN, USA, vol. 16, no. 23, 1 December 2021 (2021-12-01), Hoboken, USA, pages 3931 - 3936, XP093304040, ISSN: 1861-4728, DOI: 10.1002/asia.202100965 *

Also Published As

Publication number Publication date
WO2025052177A2 (fr) 2025-03-13

Similar Documents

Publication Publication Date Title
DE112007001469T5 (de) Collagensynthese-Promotor, der Zink als aktiven Bestandteil enthält
JPH1053532A (ja) 植物抽出物含有抗アレルギー剤
JPH09110710A (ja) 皮膚外用剤及び浴用剤
JPH0987189A (ja) エンメイソウ、ボタンピ、シソ、アルニカ含有抗アレルギー剤
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
KR101127392B1 (ko) 스피루리나 추출물을 함유하는 아토피성 피부염 예방을위한 화장료 조성물
BE903110A (fr) Derives d'ethylenediaminemonoamide
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
WO2025052177A3 (fr) Nouvelle composition et méthodes de traitement d'une maladie neurodégénérative
DE69216188T2 (de) Kosmetika und Pharmazeutika enthaltend Extensin
JPH09194385A (ja) 抗アレルギー剤及びこれを配合する皮膚外用剤あるいは 浴用剤
JP6858837B2 (ja) Ｎ−リポアミノ酸又はペプチド、誘導体及びそれらの使用
JP2640349B2 (ja) 養毛料
Barve et al. Cytotoxic, cytostatic, and keratolytic activity of anti-dandruff shampoo formulations
ATE322244T1 (de) Verwendung von polyaminosäurederivaten zur behandlung von seborrhoe und verwandten hautstörungen
EP1952799A3 (fr) Préparration cosmétique comprenant l'acide hyaluonique pour traiter les signes de vieillissement
BRPI0409912A (pt) elicitor proveniente de extratos de trigonella-foenum-gracum para o tratamento dos agentes patogênicos das plantas, utilização e processo de fabricação do referido produto
WO2023164175A3 (fr) Protacs de malt1
ATE110714T1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
WO2022031606A3 (fr) Compositions et méthodes de traitement de la maladie d'alzheimer
CN103767935A (zh) 一种中药牛膝杀菌洗手液
US20080112908A1 (en) Anti-fungal nail lacquer
Mendez et al. Preferential inhibition of bacterial elastase over human neutrophil elastase by leaf extracts of Psidium guajava: an in vitro study
JP2004002267A (ja) コラゲナーゼ阻害剤及びその利用
CN119462853B (zh) 抗菌肽cn-1及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24862167

Country of ref document: EP

Kind code of ref document: A2